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We estimated the proportion of migrants from sub-
Saharan Africa who acquired human immunodeficiency 
virus (HIV) while living in France. Life-event and clini-
cal information was collected in 2012 and 2013 from 
a random sample of HIV-infected outpatients born in 
sub-Saharan Africa and living in the Paris region. We 
assumed HIV infection in France if at least one of the 
following was fulfilled: (i) HIV diagnosis at least 11 
years after arrival in France, (ii) at least one negative 
HIV test in France, (iii) sexual debut after arrival in 
France. Otherwise, time of HIV infection was based on 
statistical modelling of first CD4+ T-cell count; infec-
tion in France was assumed if more than 50% (median 
scenario) or more than 95% (conservative scenario) of 
modelled infection times occurred after migration. 
We estimated that 49% of 898 HIV-infected adults 
born in sub-Saharan Africa (95% confidence interval 
(CI): 45–53) in the median and 35% (95% CI: 31–39) in 
the conservative scenario acquired HIV while living in 
France. This proportion was higher in men than women 
(44% (95% CI: 37–51) vs 30% (95% CI: 25–35); con-
servative scenario) and increased with length of stay 
in France. These high proportions highlight the need 
for improved HIV policies targeting migrants.
Introduction
In France, as in most countries in Western Europe, 
migrants from sub-Saharan Africa are disproportion-
ally affected by the human immunodeficiency virus 
(HIV) epidemic [1,2]. In 2012, people born in sub-Saha-
ran Africa accounted for 31% of new HIV diagnoses [3] 
and for 24% of the whole population of persons living 
with HIV (PLWHIV) in France [4], although they repre-
sented only ca 1% of the French general population [5]. 
Among people from sub-Saharan Africa, the number of 
new diagnoses has decreased in France since 2003, 
although incidence remains 29 times higher in men 
and 69 times higher in women compared with French-
national heterosexuals [6].
Most people do not know where and when they acquired 
HIV. Among migrants, HIV acquisition has long been 
considered to predominantly occur before migration 
because of generalised HIV epidemics in sub-Saharan 
African countries [7]. However, evidence from various 
European countries in the past decade suggests that 
a substantial proportion of migrants from sub-Saharan 
Africa acquired HIV while they were living in Europe 
[8]. In the United Kingdom (UK), this proportion was 
recently estimated at 31% using a modelling approach 
based on CD4+ T-cell counts [9].
Such an estimate is not currently available for most 
European countries, although it is crucial to guide 
public health monitoring and allocation of resources 
for prevention. Indeed, if HIV is acquired after migra-
tion, resources should be allocated not only to improve 
timely HIV diagnosis but also to prevent the spread of 
HIV among migrants.
In this study, in order to guide HIV policies for migrants 
in France, we estimated the proportion of sub-Saharan 
migrants who acquired HIV infection after their arrival 
in France. This estimation was performed using life-
event data and clinical data collected in the PARCOURS 
study, a large life-event survey [10] of people from sub-
Saharan Africa living in the metropolitan area of Paris, 
the French area most affected by HIV [3] and with the 
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largest population of migrants from sub-Saharan Africa 
[5].
Methods
Study design
The PARCOURS study is a cross-sectional retrospective 
life-event history survey conducted between February 
2012 and May 2013 among a random sample of sub-
Saharan migrants receiving care for HIV at hospitals in 
the Paris metropolitan area. Of the 41 hospital services 
following HIV-infected patients in the Paris region, we 
selected the 37 services where at least 100 patients 
from sub-Saharan Africa were followed up. Within 
this sampling frame, hospital services were selected 
by stratified randomisation, the sampling probability 
of each HIV service being proportional to the size of 
the service’s HIV caseload. A total of 27 services were 
chosen and 24 agreed to participate in the study. The 
caseload of these 24 services represented 72% of all 
sub-Saharan migrants followed for HIV in the Paris 
metropolitan area.
In each participating department, all outpatients born 
in a sub-Saharan African country, aged 18 to 59 years 
and diagnosed HIV-positive at least three months ago, 
were eligible. Physicians invited all eligible patients, 
except those with major cognitive or health impair-
ments, to participate and collected their written con-
sent. Professional interpreters were available on 
demand. Of a total of 1,829 eligible outpatients, 141 
were excluded, and the participation rate among the 
remaining patients was 55%, resulting in a total of 926 
participants. Among the participants, detailed informa-
tion on migration history, socioeconomic conditions, 
sexual activity and health over the lifetime was col-
lected anonymously through a standardised life-event 
questionnaire administered face-to-face by a trained 
professional interviewer independent from the clinic 
staff. The interview occurred in the clinic setting in a 
private room to ensure confidentiality. Each dimension 
of interest was documented for each year from birth 
until the time of data collection. Clinical and laboratory 
information were documented from medical records 
available in the health service where the survey was 
done. Basic data about non-participants were collected 
anonymously. There were no major differences between 
participants and non-participants in the demographic 
or clinical characteristics: the participation rate was 
higher among unemployed men compared with those 
working (60.1% vs 49.0%, p = 0.05), but did not vary 
by sex, age, or CD4+ T-cell level. Participants received 
a voucher over EUR 15. The study was approved by 
the French National Commission for Data Protection 
and Liberties (CNIL, decision DR-2011–484). The com-
plete survey protocol is registered on Clinicaltrials.gov 
(NCT02566148).
Information of interest
Information on year of HIV diagnosis was documented 
both from the participants’ reports and medical 
records. Both sources provided concordant information 
(i.e. same year +/− 1) in 81% (731/898) of the cases. 
In case of discordance, we retained the earliest date. 
Patient-reported years of arrival in France, negative HIV 
tests (if ever) and year of first intercourse were avail-
able in the life-event questionnaire. CD4+ T-cell counts 
at the time of (i) HIV diagnosis, (ii) initiation of antiret-
roviral therapy (ART) and (iii) interview were extracted 
from medical records. We defined the first measure-
ment of CD4+ T-cell count as CD4+ T-cell count at HIV 
diagnosis or, in case of missing information at diagno-
sis (n = 30), as first CD4+ T-cell count available before 
initiation of ART.
Estimation of HIV acquisition after arrival in 
France
To assess whether HIV acquisition occurred before or 
after arrival in France, we used a combined method 
mixing life-event and CD4+ T-cell data.
Based on life-event data, we considered that HIV infec-
tion had been acquired before arrival in France if HIV 
diagnosis occurred before living in France. In addi-
tion, we assumed that HIV infection had probably been 
acquired after arrival in France if at least one of the fol-
lowing life-event criteria were fulfilled: (i) HIV diagno-
sis at least 11 years after arrival in France [11,12], (ii) at 
least one negative HIV test in France, (iii) first sex after 
arrival in France. If none of these criteria was fulfilled, 
we estimated the duration from HIV infection to meas-
urement of first CD4+ T-cell count using statistical mod-
elling of the decline in CD4+ T-cell count based on a 
method previously described [13].
As we did not have information related to the serocon-
version for PARCOURS respondents, we modelled the 
decline in CD4+ T-cell using a cohort of West African 
seroconverters: the ANRS 1220 PRIMO-CI cohort of 
HIV-1 seroconverters in Abidjan, Côte d’Ivoire [13,14]. 
The PRIMO-CI cohort consisted of 351 blood donors 
(61% men; median age at HIV infection: 28.8 years; 
interquartile range (IQR): 25–34) followed from 1997 to 
2011, with documented negative and first positive HIV 
antibody test dates and at least two CD4+ T-cell counts 
available before commencement of ART or death. The 
decline in CD4+ T-cell count (square root-transformed) 
over time was estimated using a linear mixed model 
with random intercept and slope, adjusted for individ-
ual CD4+ T-cell count at first CD4+ T-cell count measure 
(x1) duration from estimated date of HIV seroconversion 
to first CD4+ T-cell count measure (x2) and age at HIV 
seroconversion (x3).* With the fixed effects obtained 
from the fitted linear mixed model in this population of 
seroconverters, we first derived a formula to estimate 
the duration Δt from HIV seroconversion to any given 
CD4+ T-cell count (CD4t):
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This formula was then used to estimate the duration 
from HIV seroconversion to first CD4+ T-cell measure-
ment before ART initiation for PARCOURS respondents.
For PARCOURS respondents, we simulated x1, x2 and 
x3 using the observed multivariate distribution in the 
PRIMO-CI seroconverters cohort. For each PARCOURS 
respondent, we simulated 500 values of x1, x2 and x3 
from a multivariate normal distribution [15] in order to 
yield 500 extrapolated durations from seroconversion 
to first measurement of CD4+ T-cell count. Then, we 
added three months to these durations to account for 
the duration between HIV infection and seroconversion.
The proportion of individuals having acquired HIV 
infection while living in France was estimated accord-
ing to two scenarios. In the median scenario, the infec-
tion in each individual was assumed to have occurred 
after arrival in France if more than 50% of the simulated 
durations fell within the period of their stay in France, 
while the conservative scenario required 95% of dura-
tions within the period of staying in France.
Associations between HIV acquisition while living in 
France according to the conservative scenario and age 
at arrival in France, time lived in France before HIV 
diagnosis, region of birth in sub-Saharan Africa and 
time point of HIV diagnosis were analysed with bivari-
ate and multivariate logistic regression models, for 
men and women separately. Multivariate models were 
adjusted for all variables mentioned above.
Data were weighted according to each individual’s 
probability of inclusion in the survey, and the weights 
applied to all percentages. Analyses were conducted 
using STATA 13.0 (Stata Corp., College Station, Texas, 
United States).
Results
Life-event or CD4+ T-cell data were missing for 28 indi-
viduals who were excluded from the analysis. Among 
the 898 respondents included, 550 were women and 
348 were men. Median age at arrival in France was 
28 years for women (IQR: 23–34) and 30 years for 
men (IQR: 25–37). Main countries of origin were Côte 
d’Ivoire (24%), Cameroon (20%), Democratic Republic 
of the Congo (13%), Mali (9%) and Congo (Brazzaville) 
(7%). The majority (81%) had at least a secondary edu-
cational level. At the time of interview, respondents 
had a median age of 43 years (IQR: 36–49; women: 40 
years (IQR: 35–46); men: 47 years (IQR: 39–52)) and 
their median length of stay in France was 12 years (IQR: 
7–20). At the time of HIV diagnosis, median time spent 
in France was three years (IQR: 1–9) and median CD4+ 
T-cell count was 274/mm3 (IQR: 129–430).
As shown in the Figure, of the 898 respondents 
included in the final study sample, 133 had been diag-
nosed with HIV before arrival in France and 765 had 
been diagnosed in France between 1983 and 2012. 
Overall 228 respondents were ascertained to have 
acquired HIV while living in France based on life-event 
criteria: 137 had been diagnosed at least 11 years after 
arrival in France, 63 had a history of negative HIV test 
in France, and 28 had their first sexual intercourse in 
France and had been infected neither perinatally nor 
through blood transfusion. Among the 537 who did 
not fulfil these criteria, based on first available CD4+ 
T-cell count, 197 were ascertained by modelling to have 
acquired HIV after arrival in France according to the 
median scenario and 69 according to the conservative 
scenario (Figure). Overall, this led to estimates of 49% 
(95% CI: 45–53) and 35% (95% CI: 31–39) of sub-Saha-
ran African migrants having acquired HIV while living 
in France, applying, respectively, the median and the 
conservative scenario.
This proportion who had acquired HIV after arrival in 
France was higher in men than in women (44% (95% 
CI: 37–51) vs 30% (95% CI: 25–35) in the conservative 
scenario) and among those who arrived in their youth 
(< 25 years-old). It increased with the length of stay 
in France after migration. After adjustment for other 
variables, the proportion increased in the groups diag-
nosed most recently (odds ratio (OR) for 2008–12 vs 
1996–2002 = 2.76 (95% CI: 0.74–10.29) for men and 
2.50 (95% CI: 1.00–6.24) for women). No difference 
was found according to educational level and region of 
birth (Table).
Discussion
To our knowledge, this study is the first to provide an 
estimate of the proportion of sub-Saharan migrants 
having acquired HIV after arrival in France.
Our estimation was based on data from a random sam-
ple of HIV-positive hospital outpatients in the greater 
Paris metropolitan area. Since this region concentrates 
the major part of PLWHIV born in sub-Saharan Africa 
living in France (69% of women and 74% of men) [16] 
and HIV care in France is essentially provided at hospi-
tal [17], our results are likely to apply to the majority of 
sub-Saharan migrants followed for HIV in France.
Our results suggest that as much as one third to half 
of sub-Saharan African migrants followed for HIV care 
in France may have acquired HIV while living in France. 
French national HIV case surveillance data previously 
showed that 28% of sub-Saharan migrants newly HIV-
diagnosed in France in 2003 to 2010 were infected 
with a B subtype, which is very rare in Africa, and 
are thus likely to have acquired HIV in Europe [18]. By 
comparison, when restricting our study to individu-
als diagnosed during the same period (since 2003, 
n = 508), we obtained an estimation of 35% (95% CI: 
29–40) in the conservative scenario. This higher esti-
mation is consistent with the fact that some migrants 
may have acquired a non-B HIV subtype in France, in 
particular within intra-African sexual networks. We 
found that men were more likely than women to have 
acquired HIV after migration. Such a result is con-
sistent with the epidemiological pattern of the HIV 
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Figure 
Assignment of HIV acquisition among Sub-Saharan African migrants living with HIV in the Paris metropolitan area, 
February 2012–May 2013 (n = 898)
Left to be assigned
Conservative scenarioc (hyp 95%)
+
+
+
Sub-Saharan migrants living
with HIV randomly recruited
in HIV hospital departments
in the Paris area 
n= 926 
Missing life-event 
or CD4+ T-cell data
n= 28
HIV diagnosed
before arrival in
France 
HIV diagnosed 11 years or 
more after arrival in France
At least one negative HIV 
test after arrival in France
Questionnaire-based method
CD4+ T-cell count method
Median scenariob (hyp 50%)
Sexual debut after arrival 
in Francea
Estimated year of infection  
after year of arrival in France
HIV acquisition after 
arrival in France (n = 425)
 49% (95% CI: 45-53)
HIV acquisition after 
arrival in France (n = 297)
 35% (95% CI: 31-39)
n= 133 n= 137
n= 63
n= 28
n= 628
Left to be assigned
n= 565
Final study sample
n= 898
Left to be assigned
n= 537
Hyp
50%
Hyp
95%
n = 197 n = 69
CI: confidence interval; HIV: human immunodeficiency virus; hyp: hypothesis.
a Infected neither perinatally nor through blood transfusion.
b HIV acquisition while living in France if > 50% of the estimated years of infection fell within the period of staying in France.
c HIV acquisition while living in France if > 95% of the estimated years of infection fell within the period of staying in France.
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epidemic in sub-Saharan Africa where women are 
infected at a younger age and to a higher proportion 
than men. Since HIV-infected men and women arrive 
approximately at the same age in France (median: 30 
and 28 years, respectively, in our sample), women are 
more likely than men to be HIV-positive at the time 
they arrive in Europe. This also indicates that men 
might be at higher sexual risk in France after migration 
than women, as already suggested in UK and in France 
[19,20]. That the likelihood of acquiring HIV while liv-
ing in France increases with time since arrival and with 
younger age at arrival further supports the validity of 
our estimation.
In the UK, 31% of black Africans born outside the UK 
and diagnosed HIV-positive between 2004 and 2010 
Men Women
Univariate Multivariate Univariate Multivariate
n Weighted
a 
% p value  OR (95% CI)   OR (95% CI)  n
Weighteda 
% p value  OR (95% CI)   OR (95% CI) 
Overall 348 43.9 550 30.0
Age at arrival in France 
< 25 years 84 78.1
< 0.001
14.49 
(6.84–30.68)
2.12 
(0.65–6.90) 171 54.1
< 0.001
11.99 
(5.30–27.13)
14.99  
(4.14–54.25)
25–34 years 139 44.3 3.06 (1.47–6.39)
0.93 
(0.31–2.84) 251 24.5
3.36 
(1.65–6.82)
4.55 
(1.72–12.03)
≥ 35 years 125 19.8 Reference Reference 128 8.4 Reference Reference
Time in France before diagnosisb 
0 to 2 years 137 10.3
< 0.001
Reference Reference 254 5.4
< 0.001
Reference Reference
3 to 5 years 45 19.3 2.25 (0.46–11.04)
2.12 
(0.44–10.34) 93 23.4
5.90 
(2.95–11.81)
6.56 
(3.00–14.32)
6 to 9 years 39 54.0 11.08 (3.44–35.66)
14.48 
(3.93–53.30) 67 52.5
21.42 
(9.95–46.10)
26.44 
(12.45–56.15)
10 years or 
more 106 93.5
117.38 
(25.78–534.49)
166.23 
(32.25–
856.71)
95 86.0 110.28 (47.48–256.13)
219.87 
(83.10–581.77)
Educational level 
None/primary 79 40.6
0.51
Reference Reference 104 30.7
0.78
Reference Reference
Secondary 160 41.1 1.02 (0.46–2.27)
2.30 
(0.88–6.03) 334 30.8
1.05 
(0.45–2.43)
1.23 
(0.65–2.32)
Higher 
education 109 50.2
1.45 
(0.67–3.11)
2.67 
(0.74–9.64) 112 27.1
0.88 
(0.28–2.83)
1.40 
(0.60–3.27)
Region of birth in sub-Saharan Africa 
Western 
Africa 199 43.5
0.67
Reference Reference 279 35.0
0.16
Reference Reference
Central Africa 141 43.6 1.00 (0.54–1.85)
1.10 
(0.48–2.48) 259 24.8
0.64 
(0.38–1.08)
0.57 
(0.32–1.01)
Eastern/
southern 
Africa
8 62.8 2.26 (0.32–15.98)
1.87 
(0.05–76.93) 12 30.2
0.87 
(0.18–4.23)
0.39 
(0.08–1.97)
Year of diagnosis 
Earlier than 
1996 49 51.7
0.61
1.73 
(0.84–3.58)
1.12 
(0.53–2.36) 67 40.3
0.14
1.58 
(0.82–3.03)
0.27 
(0.11–0.69)
1996–2002 89 38.3 Reference Reference 185 29.9 Reference Reference
2003–2007 105 45.9 1.40 (0.66–3.01)
2.88 
(1.01–8.22) 179 31.7
1.08 
(0.61–1.92)
2.39 
(1.18–4.85)
2008–2012 105 43.0 1.24 (0.51–3.02)
2.76 
(0.74–10.29) 119 22.2
0.67 
(0.33–1.35)
2.50 
(1.00–6.24)
Table
Estimated proportion of sub-Saharan African migrants living with HIV in Paris metropolitan area who acquired HIV after 
arrival in France, by sociodemographic characteristics and period of diagnosis, February 2012–May 2013 (n = 898)
CI: confidence interval; HIV: human immunodeficiency virus; OR: odds ratio.
a The Table presents the conservative scenario (hypothesis 95% ): HIV acquisition while living in France if > 95% of the estimated years of 
infection fell within the period of staying in France. Data were weighted according to each individual’s probability of inclusion in the survey 
(i.e. considering the probability of inclusion in the sample for each healthcare facility, the number of half-days of weekly consultations in 
each included facility and the individual study participation per half-day of included consultations).
b We excluded 21 men and 41 women from this multivariate analysis because data on CD4+ T-cell count at diagnosis or before initiation of 
antiretroviral therapy were unknown. 
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were estimated to have acquired HIV while living in the 
UK [9]. Consistent figures were previously estimated 
based on life histories and CD4+ T-cell count at presen-
tation in healthcare centres between 2004 and 2006 
[7]. Our results suggest that in France, the proportion 
of sub-Saharan African migrants living with HIV who 
acquired their infection after migration is even higher 
than in the UK. As in the UK, this proportion increased 
after 2000.
Rice et al. in the UK [9] estimated the time between 
HIV acquisition and diagnosis based only on modelling 
of the CD4+ T-cell decline, whereas the major strength 
of our estimation lies in the combination of life-event 
and CD4+ T-cell data. Although based on information 
given by the interviewees, histories of migratory path, 
HIV testing and sexual debut can be considered reli-
able since the life-event method greatly supports the 
recall process and the order of life events as shown 
previously [10,21]. Moreover, this mode of collection 
decreases the risk of desirability bias because the 
interviewer can compare the answers given for differ-
ent periods and fields of the life. If inconsistencies are 
detected, they can check the reliability of the answer 
with the patient and correct it. To further strengthen 
this information, we checked the consistency between 
dates and circumstances of the negative HIV test in 
France and other life events such as pregnancies and 
sexual partnerships (data not shown). We assumed 
that patients acquired HIV only through sexual inter-
course because less than 1% of sub-Saharan migrants 
living with HIV in France have been documented as IDU 
(data not shown, ANRS-VESPA study).
We used CD4+ T-cell modelling to estimate the time 
between HIV acquisition and diagnosis only when the 
life-event criterion did not allow us to assign HIV acqui-
sition before or after arrival in France. We modelled the 
natural decline in CD4+ T-cell counts from a cohort of 
seroconverters in West Africa [14] to take into account 
possible genetic specificity of CD4+ T-cell decline in 
HIV infection [22]. Since HIV disease progression does 
not differ across individuals from western and central 
Africa [23], estimates of the decline in CD4+ T-cell count 
based on data from Côte d’Ivoire are likely to apply to 
our study population which consisted mostly of people 
originating from these two regions (96%). The model 
was also checked on data with life-event criterion 
available, and the results were consistent. 
Our study has some limitations. Firstly, the natural his-
tory of HIV infection may be slightly different between 
African people living in Europe and those living in 
Africa: Pantazis et al. have shown that time between 
HIV infection and a certain level of CD4+ T-cells is 
shorter in African people diagnosed for HIV in Europe 
than in African people diagnosed in sub-Saharan Africa 
[22]. In that case our modelling hypotheses would 
slightly underestimate the proportion of sub-Saharan 
African HIV-positive patients having acquired HIV after 
arrival in France.
Secondly, our estimation does not take into account 
HIV-positive migrants who are undiagnosed (estimated 
at ca one in four migrants with HIV [24]) or not in care. 
In France, migrants have free access to care after three 
months of residence, regardless of legal status. But it 
is still possible that some of them, in particular when 
recently infected and healthy, delayed their entry in 
care. This suggests that we may have underestimated 
the proportion of sub-Saharan African migrants living 
with HIV and having acquired HIV while living in France.
Thirdly, among PARCOURS participants, 1.3% were 
infected with HIV-2. Among them, some were assigned, 
based on life-event data, as having acquired HIV before/
after arrival, leaving only 0.9% to whom we applied 
the slope of CD4+ T-cell counts modelled for HIV-1. It 
is possible that for these 0.9%, we over-estimated the 
HIV-2 acquisition in France because the decline of CD4+ 
T-cells is slower in HIV-2 infection. However, consider-
ing this low proportion, this is unlikely to have affected 
our overall results. 
Finally, our sample was not large enough to investigate 
HIV acquisition in France among men who have sex with 
men (MSM): only 5% (n = 18) of the male participants 
declared having had male partners in their lifetime. The 
estimated proportion of post-migration HIV acquisition 
in this group did not appear significantly different from 
non-MSM. Nevertheless migrant MSM may be at high 
risk due to higher stigma and should be targeted in HIV 
prevention policies.
Conclusion
Despite possible underestimation, we estimated high 
levels of HIV acquisition after migration, which under-
mine the predominant postulate of HIV as a mainly 
imported epidemic among African migrants in Europe. 
It seems important that other European countries 
attempt to quantify post-migration HIV acquisition 
among migrants [25]. These results are necessary to 
guide allocation of prevention resources as in most 
countries in Europe, few prevention resources are 
allocated to activities targeting migrants because it 
is assumed that they were infected before arrival. 
Our results for France emphasise the need for a bet-
ter understanding of sexual and preventive behaviour 
after migration to address the unmet preventive needs 
in the population born in sub-Saharan Africa and to 
design tailored public health policies in France.
*Erratum
This sentence was erroneously published as “The decline in 
CD4+ T-cell count (square root-transformed) over time was 
estimated using a linear mixed model with random intercept 
and slope, adjusted for individual CD4+ T-cell count at first 
CD4+ T-cell count measure (x1) duration from estimated date 
of HIV seroconversion to first CD4+ T-cell count measure (x1) 
and age at HIV seroconversion (x1).” The variables were cor-
rected on 20 November 2015. We apologise for this mistake.
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Further members of the PARCOURS Study Group:
E. Rodary, D. Pourette, J. Situ, P. Revault, P. Sogni, J. Gelly, Y 
le Strat, N Razafindrasitma.
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